John Taylor, new Idera Pharmaceuticals CEO
As lead drug flopped and AbbVie collab dissolved, cancer biotech resorts to buying rare disease company
Ever since disappointing late-stage data on its cancer drug tanked Idera Pharmaceuticals’ stock last year (unhelped by an ill-fated collaboration with AbbVie), execs …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
